AIF1 and Alzheimer disease: Interestingly, in older (> 80 years) AD patients, the removal of amyloid plaques using anti-Aβ immunotherapy results in an increase in IBA1 expression, although this does not correlate with either total Aβ burden or Aβ(1–42) levels [20].